WOIPPY, France–(BUSINESS WIRE)–Regulatory News: ABL Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6) (the “Company”), a company specializing in molecular diagnostic solutions, healthcare software and clinical research services, announces that it has signed, alongside Advanced Biological Laboratories S.A. (ABL), its parent company, a non-binding letter of intent for a proposed acquisition of 100% of the share capital of Vela Operations Singapore Pte. Ltd. and Vela Diagnostics USA Inc. T